STOCK TITAN

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Atopic Dermatitis

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Celldex (CLDX) is discontinuing barzolvolimab development in atopic dermatitis after its Phase 2 study missed the main efficacy goal. Neither dose met the Week 16 itch endpoint: itch scores fell 29.2% from baseline with 300 mg and 16.2% with 150 mg, versus 19.5% with placebo. Key secondary endpoints were also missed, and the study did not meet Celldex's threshold for continuing development.

Both doses reduced circulating tryptase, a sign of mast cell depletion, and barzolvolimab was well tolerated. Celldex plans a 2027 biologics license application for chronic spontaneous urticaria, where both Phase 3 trials met their primary and key secondary endpoints at 12 weeks. Phase 3 studies are enrolling in cold urticaria and symptomatic dermographism, and Celldex plans to announce additional uses under study by year-end.

Loading...
Loading translation...
7 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointBoth Phase 3 chronic spontaneous urticaria trials met their primary and all key secondary endpoints at 12 weeks
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Chronic spontaneous urticaria filing is planned for 2027 as a biologics license application for barzolvolimab
  • Minor pointPhase 3 studies in cold urticaria and symptomatic dermographism are actively enrolling
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional barzolvolimab indications are slated for announcement by year-end
  • Minor pointAtopic dermatitis safety and tolerability were favorable with both dosing regimens, consistent with prior studies
2 minor points
  • Minor pointCirculating tryptase fell with both doses, indicating systemic mast cell depletion; the reduction was sustained during treatment
  • Minor pointPhase 3 chronic spontaneous urticaria safety was favorable in the reported results

Negative

  • Major pointWeek 16 itch endpoint missed statistical significance at both doses: scores fell 29.2% with 300 mg and 16.2% with 150 mg versus 19.5% with placebo
  • Minor pointAtopic dermatitis development is being discontinued after results fell short of Celldex's internal threshold
  • Minor pointKey secondary endpoints for eczema severity and investigator-rated skin clearance did not meaningfully differ from placebo
  • Minor pointLonger treatment showed no improvement on the primary or key secondary endpoints at Week 32

Key Figures

Study size: 131 patients PP-NRS change, 300 mg: -29.2% vs. -19.5% placebo; difference -9.7 (90% CI: -21.7, 2.4); p=0.187 PP-NRS change, 150 mg: -16.2% vs. -19.5% placebo; difference 3.3 (90% CI: -8.7, 15.3); p=0.651
Study size
131 patients
Phase 2 atopic dermatitis study
PP-NRS change, 300 mg
-29.2% vs. -19.5% placebo; difference -9.7 (90% CI: -21.7, 2.4); p=0.187
Week 16; primary endpoint
PP-NRS change, 150 mg
-16.2% vs. -19.5% placebo; difference 3.3 (90% CI: -8.7, 15.3); p=0.651
Week 16; primary endpoint

Previous Clinical trial Reports

1 past event · Latest: Jul 21
Same Type 1 event
  1. Jul 21

    Phase 2 trial results

    24h Move
    -2.5%

    Prurigo nodularis study missed endpoints despite mast-cell depletion; Celldex discontinued development.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

easi, iga
2 terms
easi medical
"Eczema Area and Severity Index (EASI) score"
Eczema Area and Severity Index (EASI) is a standardized clinical score used to measure the extent and intensity of atopic dermatitis (eczema) on a patient’s body, combining how much skin is affected and how severe symptoms like redness and thickness are. For investors, EASI matters because it is often a primary endpoint in dermatology drug trials: larger or faster improvements in EASI can increase the chance of regulatory approval and commercial success, much like a clear test score can boost confidence in a new product.
iga medical
"Investigator's Global Assessment (IGA) score of 0 or 1"
IgA (immunoglobulin A) is an antibody that acts like a first-line security guard on the body's surfaces—such as the gut, respiratory tract and eyes—helping block infections and clear harmful substances. For investors, IgA matters because it is a target and a biomarker in diagnostics and drug development for infections, autoimmune conditions and some kidney diseases; changes in IgA levels can influence clinical trial outcomes, regulatory decisions and market demand for treatments and tests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Study did not meet key efficacy measures or internal hurdle rate for continued development
  • Systemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction in serum tryptase
  • Favorable safety and tolerability demonstrated, consistent with prior studies
  • BLA submission for barzolvolimab in CSU anticipated in 2027
  • Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling
  • Additional indications for barzolvolimab to be announced by year end

HAMPTON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab in moderate to severe atopic dermatitis (AD). Barzolvolimab, a first-in-class humanized monoclonal antibody with a novel mechanism of action that uniquely targets the KIT receptor and depletes mast cells, is being studied across multiple indications where mast cells are implicated in the disease pathology. The primary endpoint of the Phase 2 AD study, the percent change from baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16 compared to placebo, and key secondary endpoints were not met. While some benefit from barzolvolimab treatment was observed, these improvements did not meet the Company’s internal hurdle rate for continued development. Data suggest that while mast cells contribute to AD, they are not a primary driver of the disease. Based on these results, Celldex is discontinuing development in AD. Consistent with previously reported studies, barzolvolimab demonstrated a favorable safety and tolerability profile.

“Celldex is leading the exploration of mast cell science to understand the contribution of mast cells to various diseases and how targeted mast cell depletion can best be implemented to improve the lives of patients,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. “We have delivered best in disease data in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism while also increasing our understanding of which diseases, like atopic dermatitis, might not be primarily driven by mast cells. We are thankful to the patients and investigators who have played an important role in furthering this science. We remain focused on delivering on barzolvolimab’s promise for patients and look forward to announcing additional indications for barzolvolimab based on learnings to date, while also advancing our planned 2027 BLA submission in CSU and executing across our Phase 3 studies in CSU, symptomatic dermographism and cold urticaria.”

In the Phase 2 AD study, 131 patients from 28 US-based centers were randomized in a 1:1:1 ratio to receive subcutaneous injections of barzolvolimab at either 150 or 300 mg every 4 weeks after an initial loading dose of 450 mg or placebo during a 16-week placebo-controlled treatment phase. Patients then entered a 16-week active treatment period, in which patients in the 150 mg and 300 mg dose groups continued to receive barzolvolimab at the same dose, while patients randomized into the placebo arm were re-randomized into one of the two active treatment arms. The primary endpoint of the study evaluates the percent improvement of the two barzolvolimab dose levels compared to placebo using the Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 16. The study is 80% powered with a type I error of p=0.1. Key secondary endpoints include the percentage improvement in Eczema Area and Severity Index (EASI) score and proportion of patients achieving an Investigator's Global Assessment (IGA) score of 0 or 1.

Summary of Key Findings

  • The primary endpoint, percent change from baseline (CFB) in the weekly average of the daily PP-NRS score at Week 16, did not meet statistical significance (p=0.1) at either dose evaluated. At Week 16, percent CFB was -19.5% for placebo compared to -29.2% for 300mg Q4W [Diff (90% CI): -9.7 (-21.7, 2.4); p=0.187] and -16.2% for 150mgQ4W [Diff (90% CI): 3.3 (-8.7, 15.3); p=0.651].
  • The change from baseline EASI score and the percentage of patients with IGA 0/1, key secondary endpoints, did not meaningfully differentiate from placebo.
  • There was no improvement observed with longer treatment across the primary and key secondary endpoints (Week 32).
  • While there were numerical differences from placebo observed, these improvements did not meet the Company’s internal requirements for continued development.
  • Rapid and profound suppression of circulating tryptase, indicative of systemic mast cell depletion, was observed with both doses. The addition of the 450 mg loading dose led to early, profound tryptase reduction that was sustained over the duration of the treatment period.
  • Barzolvolimab was well tolerated. Loading dose (450 mg) followed by Q4W dosing (150 or 300 mg) demonstrated a favorable safety profile consistent with prior studies.

For additional information on this trial (NCT06727552), please visit www.clinicaltrials.gov.

About Barzolvolimab
Barzolvolimab is a first-in-class humanized monoclonal antibody with a novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease. Based on data from robust, randomized, placebo controlled Phase 2 and 3 studies, barzolvolimab has significant potential as a first-in-class and best-in-disease treatment option for patients with chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is currently being studied in Phase 3 studies in CSU, ColdU and SD with additional indications planned for the future. In September 2026, Celldex reported topline data from the Phase 3 studies in CSU—the primary and all key secondary endpoints were met across both studies at 12 weeks and a favorable safety profile was demonstrated. Treatment continues in both trials to 52 weeks and a BLA submission is planned for 2027.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.

Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our current expectations regarding the submission of a Biologics License Application (“BLA”) to the FDA in 2027; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Elizabeth Higgins
Executive Director, Investor Relations & Corporate Communications
(857) 404-2088
ehiggins@celldex.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Celldex stop developing barzolvolimab for atopic dermatitis?

Celldex is stopping development because the Phase 2 results fell short of its threshold for continuing. Neither dose met the primary itch endpoint at Week 16, and the key secondary measures for eczema severity and investigator-rated skin clearance did not meaningfully differ from placebo.

Did patients improve with longer barzolvolimab treatment in Celldex's atopic dermatitis trial?

The study found no improvement at Week 32 across the primary itch endpoint and key secondary endpoints. After the first 16 weeks, patients already on barzolvolimab stayed on their assigned dose, while patients on placebo were randomized to one of the two active doses.

Keep reading